The objective of this study was to investigate the genotype-phenotype correlation of the PAX6 gene in aniridia. We clinically examined 5 families and 16 sporadic patients with aniridia. We performed chromosomal analysis and PCR analysis of the PAX6 gene using patient genomic DNA. Chromosomal analysis demonstrated deletions at 11p13 in one allele in four sporadic patients. Seven nonsense mutations, two frameshifts (two insertions), four splice junction errors and two missense mutations were found, and all were heterozygous. The iris phenotype ranged from total to normal in each patient, and the characteristic phenotypes, including cataract, glaucoma or optic nerve hypoplasia, varied widely even among members of the same family. Foveal hypoplasia was detected in all patients except for one. No obvious genotype-phenotype correlation was identified; however, the aniridia phenotype between the two eyes in each patient was quite similar in all patients. Because PAX6 regulates numerous downstream genes and its expression is regulated by several factors during eye development, the aniridia phenotype may be complex even in family members. However, because PAX6 regulation, resulting from both paternal and maternal alleles associated with PAX6, is considered to be roughly similar in both eyes of each patient, the aniridia phenotype may be similar in both eyes of each patient.
INTRODUCTION
It is well known that aniridia is caused by mutation of the PAX6 gene. 1, 2 The PAX6 gene codes a transcriptional regulator and is a master control gene in the development of ocular tissues in invertebrates. 3 This is evident from the ectopic formation of eyes on the wings, legs and antennae in Drosophila upon targeted expression of the eyeless gene, a homolog of the human PAX6. 4 Furthermore, an expression pattern of the Pax6 gene also indicates the multiple functions of the gene in mammals. 5 In situ hybridization for murine Pax6 demonstrated its expression in the developing central nervous system as well as in ocular tissues derived from the ectoderm and neuroectoderm, that is, the corneal epithelium, lens and retina. 6 These findings can explain various phenotypic manifestations in the entire eye of aniridia patients, including corneal opacity, absence of the iris, glaucoma, cataract and hypoplasia of the fovea and optic nerve. These findings also present the possibility that mutations of the PAX6 gene cause a variety of developmental anomalies of ocular tissues. In addition to aniridia, PAX6 mutations have been reported in Peters' anomaly, 7 corneal dystrophy 8 and foveal hypoplasia. 9 The PAX6 gene was isolated as a candidate aniridia gene by positional cloning from an overlapping region of chromosomal deletions at 11p13, which are observed in some aniridia patients, especially in those with Wilms' tumor, genitourinary abnormalities and mental retardation (WAGR syndrome). 1 In addition to large deletions encompassing the whole gene, more than 330 mutations have been detected in autosomal dominant and sporadic aniridia patients. 10 Because most of these mutations are nonsense, frameshifts or splicing errors that result in premature translational termination on one of the alleles, 11 haploinsufficiency of the gene, 12 or the presence of one amorphic allele, has been suggested to cause the aniridia phenotype. 13 We recently identified five additional PAX6 missense mutations in four pedigrees.
14 These findings indicate that hypomorphic alleles that significantly disturb an important motif also cause the aniridia phenotype. While different genotypic mutations cause different phenotypes of developmental anomalies, the same PAX6 mutation sometimes resulted in a variety of aniridia phenotypes that ranged from normal-sized irises to the complete absence of the iris in one pedigree, 15 which indicated that one genotype produces different phenotypes of aniridia. Thus, the genotype-phenotype correlation of PAX6 mutations in aniridia is still controversial. In the present study, we investigated the correlation between the genotype of amorphic or hypomorphic PAX6 mutations and the phenotype of aniridia.
MATERIALS AND METHODS

Patients and clinical data
The study included five families (autosomal dominant trait) and 16 sporadic patients with aniridia. Visual acuity was examined by Landordt's ring procedure, and examination of ocular anterior and posterior segments was performed with a slit-lamp biomicroscope and a binocular indirect ophthalmoscope. Glaucoma was diagnosed by measurement of intraocular pressure, examination of the iridocorneal angle, a slit-lamp biomicroscope, and visual field measurement if available. Full-field electroretinographies (ERGs) were recorded in six patients (Patient no. 12, 19 and 21-24) according to the International Society for Clinical Electrophysiology of Vision (ISCEV) standards. Some examinations in infants were performed under general anesthesia when necessary.
Optic nerve hypoplasia was diagnosed when the ratio of DM (the distance from disc to macular) to DD (the mean disc diameter) was greater than 3.2 and the disc showed a typical double ring sign, simultaneously. The pediatrician also evaluated systemic and neurological findings, and screening for the presence of Wilms' tumor was performed by echography. 
Chromosomal and genetic analysis
These studies were conducted in accordance with the Declaration of Helsinki. Our use of human subjects was conducted with patients' informed consent, and approved by the Ethics Committee of National Center for Child Health and Development (Approval no. 518). Blood samples of the patients and family members were collected from the peripheral veins. High-resolution G-banded chromosomes were obtained from phytohemagglutinin -synchronized blood lymphocyte culture after 72 h. Twenty metaphases were analyzed. Genomic DNA was prepared from isolated leukocytes using a standard procedure. 14 For mutation analysis, the extracted DNA was amplified using PCR primer sets (Supplementary Table S1) for 13 exons of PAX6 (NCBI; M93650; http://www.ncbi.nlm.nih.gov/nuccore/189632/) under the PCR conditions previously described. 16 The PCR product was purified and directly sequenced using the BigDye Terminator v3.1 Cycle Sequencing Kit on an ABI 3100 autosequencer (Applied Biosystems, MA, USA), as previously described. 17 The sequences were compared with the reference in the database at the National Center for Biotechnology Information (NCBI; NC_000011.9; http://www.ncbi.nlm.nih.gov/nuccore/NC_000011.9).
RESULTS
Clinical findings
The lists of clinical phenotypes associated with mutations and chromosomal defects are summarized in Tables 1 and 2 , respectively. Regarding the aniridia phenotype, the iris was totally absent in 50 eyes (89%), partially absent in 4 eyes (7%) and had an almost normal appearance in 2 eyes (4%). Corneal opacity was observed in 10 eyes (18%), congenital or developmental cataract in 50 eyes (89%), glaucoma in 12 eyes (21%), foveal hypoplasia in 54 eyes (96%) and optic nerve hypoplasia in 2 eyes (4%). Visual acuity ranged from 0.06 to 0.6 but was not greater than 0.3 in any of the eyes except for both eyes of Patient no. 11 without foveal hypoplasia. Wilms' tumor, hepatoblastoma and polydactylia were observed in one patient each, and mental retardation was observed in three patients. A series of ERGs was obtained from six patients 
PAX6 mutations
Seven nonsense mutations located in exons 5-11 of the PAX6 gene, including two frameshifts (two insertions), four splicing errors and two missense mutations, were found in five families and 12 sporadic patients. Among those mutations, eight mutations were associated with PD, two with the linking region, two with the homeodomain and four with PST. Of these nonsense mutations, frameshifts and splicing errors, the transcripts of mRNA were likely degraded by nonsense-mediated decay. 18 Patient no. 3 had two mutations: a nonsense mutation (p.Q27X) in exon 5 and a splicing error in intron 6. These mutations were not found in his parents or siblings (data not shown). Novel mutations, including c.79C4T (p.Gln27X), c.109_110insG (p.Ala2GlyfsX19), IVS5+1G4T, IVS5+2T4G, c.551_552insG (p.Glu9ArgfsX15), c.802G4T (p.Glu268X) and IVS11+1G4T, were identified in the current Genotype-phenotype correlation in Aniridia T Yokoi et al study. As previously reported, the two missense mutations c.131G4A (p.Arg44Gln) and c.50A4G (p.Asn17Ser) were found in two sporadic patients.
Genotype-phenotype correlation Although PAX6 mutations were found throughout the region from exon 5 to 11, where the PD to PST was coded, no clear correlation was identified between phenotype and genotype. Moreover, even in members of the same family who had the same mutation, the phenotype of aniridia was partially different: the appearances of corneal opacity and glaucoma were variable in family no. 1; the appearance of corneal opacity was variable in family no. 2; the appearances of iris remnant, cataract and foveal hypoplasia were variable in family no. 3; and the appearance of optic nerve hypoplasia was variable in family no. 4. ERG also showed variation even in Patient no. 22-24 who had the same IVS11+1G4T mutation. However, all ocular findings were almost completely symmetrical in both eyes of each patient.
Chromosomal anomalies A chromosomal deletion including 11p13 was detected in four sporadic patients. In all of the affected eyes, one of which also had posterior lenticular cyst, the iris and fovea were totally absent, and cataracts were observed. Patients with severe phenotype accompanied with cloudy cornea and glaucoma showed mental retardation, and one of the patients was affected by Wilms' tumor, while the other had polydactylia. Those two patients were clinically considered to have WAGR syndrome before chromosomal analysis.
DISCUSSION
The present study demonstrated some novel genotypes of the PAX6 gene in aniridia. Patient no. 3 had two mutations, a nonsense mutation (p.Q27X) in exon 5 and a splicing error in exon 6. It is well known that PAX6 mutations' effects are dose-dependent, 19 and the abnormalities depend on the severity of the mutation of PAX6. In mutants of the small eye (Sey) locus, where the murine homolog of the PAX6 gene is located, 20 the inactivation of both alleles causes the eyes not to develop and results in severe craniofacial disorders, 21 whereas inactivation of one allele results in the development of small eyes and mild central nervous system disorders, the latter of which are detectable only at the embryonic stage. In humans, compound heterozygotes are usually embryonic lethal, but two cases have survived with no or small eyes and central nervous system disorders. 19, 22 In the present study, Patient no. 3 exhibited only aniridia; thus, the two mutations may be present in one allele and the former one (p.Q27X) first terminates the PAX6 protein.
Three chromosomal abnormalities of 11p13 and seven nonsense mutations, two frameshifts and four splicing errors of the PAX6 gene were found in our patients. Although some mutations in the PST region are reported to cause run-on translation into the 3'UTR, which results in a dominant negative mutation and a severe aniridia phenotype, 23, 24 all mutations in the current study were limited in location from exon 5 to exon 11 and likely induced haploinsufficiency caused by nonsense mediated decay. The other two missense mutations in the N-terminal subdomain of the paired domain had already been identified in Japanese patients, 14 which confirmed that significant disturbance of an important motif by the hypomorphic allele also causes the aniridia phenotype.
In our aniridia patients, an obvious genotype-phenotype correlation was not observed. Although haploinsufficiency of the PAX6 gene causes aniridia, which is associated with characteristic phenotypes including iris hypoplasia, foveal hypoplasia, cloudy cornea, glaucoma and cataract, the variety of the phenotype was not totally correlated with the genotype. In the current study, even among the same family members, the aniridia phenotype varied widely. Notably, in family no. 5, the father (Patient no. 24) exhibited less severe iris hypoplasia than his son (Patient no. 23); however, the ERGs demonstrated a more severely abnormal phenotype than the son, which also suggested that the phenotype was variable even in patients carrying the same mutation. In a spatio-temporal manner, Pax6 regulates various downstream targets, including Ngn2, Lews X, Wnt7b and δ-crystallin, 25 and Pax6 is regulated by at least six enhancer regions, three promoters, including P0, P1 and Pα, 26 and sometimes by Pax6 itself. In addition, co-activators, such as Sox2 and Maf, 27 and co-repressors, such as Smad3 28 and Nkx6.1, 29 also have vital roles in the expression of downstream targets of Pax6. This complex gene expression associated with PAX6, which is regulated by both paternal and maternal alleles, may result in phenotypic variation even in cases with the same PAX6 genotype. Simultaneously, both of the eyes of each patient, which have the same PAX6 genotype and associated regulatory mechanisms, may exhibit almost identical phenotypes.
